DE602005013244D1 - Pharmazeutische zusammensetzungen für die kontroll - Google Patents

Pharmazeutische zusammensetzungen für die kontroll

Info

Publication number
DE602005013244D1
DE602005013244D1 DE602005013244T DE602005013244T DE602005013244D1 DE 602005013244 D1 DE602005013244 D1 DE 602005013244D1 DE 602005013244 T DE602005013244 T DE 602005013244T DE 602005013244 T DE602005013244 T DE 602005013244T DE 602005013244 D1 DE602005013244 D1 DE 602005013244D1
Authority
DE
Germany
Prior art keywords
biologically active
methods
provides
subject
controlled release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602005013244T
Other languages
English (en)
Inventor
Li Yuhua
Benjamin Chien
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
QPS LLC
Original Assignee
QPS LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by QPS LLC filed Critical QPS LLC
Publication of DE602005013244D1 publication Critical patent/DE602005013244D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/541—Organic ions forming an ion pair complex with the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/548—Phosphates or phosphonates, e.g. bone-seeking
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
DE602005013244T 2004-08-12 2005-08-11 Pharmazeutische zusammensetzungen für die kontroll Active DE602005013244D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60090704P 2004-08-12 2004-08-12
PCT/US2005/028676 WO2006017852A2 (en) 2004-08-12 2005-08-11 Pharmaceutical compositions for controlled release delivery of biologically active compounds

Publications (1)

Publication Number Publication Date
DE602005013244D1 true DE602005013244D1 (de) 2009-04-23

Family

ID=35839986

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005013244T Active DE602005013244D1 (de) 2004-08-12 2005-08-11 Pharmazeutische zusammensetzungen für die kontroll

Country Status (21)

Country Link
US (1) US7964219B2 (de)
EP (1) EP1786400B1 (de)
JP (1) JP5053846B2 (de)
KR (1) KR101231856B1 (de)
CN (1) CN101035512B (de)
AT (1) ATE424848T1 (de)
AU (1) AU2005271242B9 (de)
BR (1) BRPI0514297A (de)
CA (1) CA2576689C (de)
CY (1) CY1109425T1 (de)
DE (1) DE602005013244D1 (de)
DK (1) DK1786400T3 (de)
ES (1) ES2323141T3 (de)
HK (1) HK1108638A1 (de)
MX (1) MX2007001760A (de)
NZ (1) NZ553149A (de)
PL (1) PL1786400T3 (de)
PT (1) PT1786400E (de)
RU (1) RU2390355C2 (de)
SI (1) SI1786400T1 (de)
WO (1) WO2006017852A2 (de)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0514297A (pt) * 2004-08-12 2008-06-10 Quest Pharmaceutical Services composições farmacêuticas para liberação controlada de compostos biologicamente ativos
ITRM20050344A1 (it) * 2005-06-30 2007-01-01 Luca Maria De Sali o complessi di sostanze metil-donatrici con acido fitico o suoi derivati e relativo metodo di sintesi.
MX2008002370A (es) 2005-08-19 2008-04-29 Amylin Pharmaceuticals Inc Exendina para tratar la diabetes y reducir el peso del cuerpo.
KR20140133968A (ko) * 2005-12-22 2014-11-20 노파르티스 아게 옥트레오티드 및 ２종 이상의 폴리락티드-코-글리콜리드 중합체를 포함하는 서방형 제제
EP1984009B1 (de) * 2006-01-18 2012-10-24 Qps, Llc Pharmazeutische zusammensetzungen mit verbesserter stabilität
ES2403645T5 (es) * 2006-06-22 2020-11-16 Biocompatibles Uk Ltd Producto farmacéutico rehidratable
EP1917971A1 (de) * 2006-10-27 2008-05-07 Société de Conseils de Recherches et d'Applications Scientifiques ( S.C.R.A.S.) Zusammensetzungen mit verlängerter Wirkstofffreigabe, enthaltend Polymere mit sehr niedrigem Molekulargewicht
KR100805208B1 (ko) * 2007-03-27 2008-02-21 주식회사 펩트론 엑센딘 함유 서방성 제제 조성물, 엑센딘 함유 서방성미립구 및 이의 제조 방법
DK2157967T3 (da) * 2007-04-23 2013-04-08 Intarcia Therapeutics Inc Suspensionsformuleringer af insulinotropiske peptider og anvendelser deraf
EP2187911A1 (de) * 2007-09-11 2010-05-26 Mondobiotech Laboratories AG Verwendung von peptid yy, allein oder in kombination mit glucagon-artigem peptid, zur verwendung in der medizin
US8551072B2 (en) 2007-12-12 2013-10-08 Boston Scientific Scimed, Inc. Methods, devices and compositions for controlled drug delivery to injured myocardium
WO2009091622A1 (en) * 2008-01-18 2009-07-23 Dow Global Technologies Inc. Method to enhance aqueous solubility of poorly soluble actives using methoxypolyethylene glycol
EP2303313B1 (de) 2008-05-21 2015-10-28 Amylin Pharmaceuticals, LLC Exendine zur senkung der cholesterin- und triglyceridwerte
WO2009148583A2 (en) * 2008-06-03 2009-12-10 Qlt Usa, Inc. Method for improvement of octreotide bioavailability
EP2213307A1 (de) * 2009-02-03 2010-08-04 Novartis AG Injizierbare Depotformulierungen
ES2600797T3 (es) * 2008-08-12 2017-02-10 Novartis Ag Composiciones farmacéuticas
JP5472756B2 (ja) 2008-10-02 2014-04-16 マイラン・インク 多層接着ラミネートの作製方法
US20100086597A1 (en) * 2008-10-06 2010-04-08 Oakwood Laboratories LLC Microspheres for the sustained release of octreotide with a low initial burst
EP2421517A4 (de) * 2009-04-23 2013-08-07 Sustained Nano Systems Llc Spendevorrichtung mit gesteuerter ausgabe
WO2010133961A1 (en) 2009-05-22 2010-11-25 Inventia Healthcare Private Limited Extended release compositions of cyclobenzaprine
WO2011005939A2 (en) 2009-07-09 2011-01-13 Mayo Foundation For Medical Education And Research Long acting atrial natriuretic peptide (la-anp) and methods for use thereof
US20120172456A1 (en) 2009-09-10 2012-07-05 Little Steven R Engineered microparticles for macromolecule delivery
LT2462246T (lt) * 2009-09-28 2017-11-27 Intarcia Therapeutics, Inc Esminio stacionaraus vaisto tiekimo greitas įgyvendinimas ir (arba) nutraukimas
SG183363A1 (en) * 2010-02-22 2012-09-27 Edge Therapeutics Inc Methods and compositions to treat hemorrhagic conditions of the brain
KR101319420B1 (ko) * 2011-03-18 2013-10-17 한남대학교 산학협력단 서방형 방출이 가능한 수용성 양이온 약물 전달 시스템
EP2751136B1 (de) 2011-08-30 2017-10-18 Mayo Foundation For Medical Education And Research Natriuretische polypeptide
US9611305B2 (en) 2012-01-06 2017-04-04 Mayo Foundation For Medical Education And Research Treating cardiovascular or renal diseases
CN102552166A (zh) * 2012-01-09 2012-07-11 北京化工大学 一种溶菌酶/聚(α-氰基丙烯酸异丁酯)载药微球的制备方法
CN102552169B (zh) * 2012-02-17 2015-07-29 深圳市健元医药科技有限公司 一种醋酸阿肽地尔缓释微球制剂及其制备方法
EP2849723B1 (de) 2012-05-18 2018-05-02 Genentech, Inc. Hochkonzentrierte monoklonale antikörperformulierungen
US9040034B2 (en) 2013-04-09 2015-05-26 International Business Machines Corporation Vitamin functionalized gel-forming block copolymers for biomedical applications
WO2015088990A1 (en) 2013-12-09 2015-06-18 Durect Corporation Pharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same
CN103720663B (zh) * 2014-01-08 2016-04-06 昆药集团股份有限公司 一种促卵泡激素缓释微球及其制备方法
US10548885B2 (en) * 2014-07-09 2020-02-04 Pierre Fabre Medicament Method for treating movement disorders with befiradol
US9744209B2 (en) 2015-01-30 2017-08-29 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9687526B2 (en) 2015-01-30 2017-06-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9750785B2 (en) 2015-01-30 2017-09-05 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9375478B1 (en) 2015-01-30 2016-06-28 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9925233B2 (en) 2015-01-30 2018-03-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9937223B2 (en) 2015-01-30 2018-04-10 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
RU2726777C2 (ru) * 2015-06-12 2020-07-15 Ново Нордиск А/С Селективные соединения пептида yy и их применения
CA3036235A1 (en) 2016-09-09 2018-03-15 Irisys, Inc. Lipsomal anticancer compositions
EP3538131A4 (de) 2016-11-09 2020-07-01 Mayo Foundation for Medical Education and Research Manp-analoga
DE102016013737A1 (de) * 2016-11-17 2018-05-17 WindplusSonne GmbH Hexahydroxycyclohexanhexaphosphorsäureestersalze zur Behandlung von Kalzinose sowie diätische Lebensmittel mit Hexahydroxycyclohexanhexaphosphorsäureestersalzen als Zusatzstoffe
IL271908B2 (en) 2017-07-11 2024-02-01 Sustained Nano Systems Llc Over-compressed pharmaceutical preparations
CA3069155A1 (en) 2017-07-11 2019-01-17 Sustained Nano Systems Llc Radiation sterilization of hypercompressed polymer dosage forms
KR102137786B1 (ko) * 2018-07-19 2020-07-24 주식회사 아울바이오 주사제용 미립구의 제조방법
KR102639578B1 (ko) 2018-10-15 2024-02-21 주식회사 종근당 주사 가능한 장기-지속형 날트렉손 마이크로입자 조성물
US11633416B1 (en) 2020-03-06 2023-04-25 Arcus Biosciences, Inc. Oral formulations of CD73 compounds
CN112661958B (zh) * 2020-12-09 2023-03-17 中山大学 一种基于肌醇和精氨酸的聚酯酰胺及其制备方法与应用

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US5059591B1 (en) * 1983-05-26 2000-04-25 Liposome Co Inc Drug preparations of reduced toxicity
US4578384A (en) * 1984-02-15 1986-03-25 The United States Of America As Represented By The Secretary Of The Army Polylactic-polyglycolic acids combined with an acidic phospholipid-lysozyme complex for healing osseous tissue
JP2551756B2 (ja) 1985-05-07 1996-11-06 武田薬品工業株式会社 ポリオキシカルボン酸エステルおよびその製造法
US6312679B1 (en) 1986-08-18 2001-11-06 The Dow Chemical Company Dense star polymer conjugates as dyes
US4728202A (en) * 1987-01-14 1988-03-01 Emerson Electric Co. Shaft locking collar for bearing assemblies
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5538739A (en) 1989-07-07 1996-07-23 Sandoz Ltd. Sustained release formulations of water soluble peptides
US5077049A (en) 1989-07-24 1991-12-31 Vipont Pharmaceutical, Inc. Biodegradable system for regenerating the periodontium
US5225205A (en) 1989-07-28 1993-07-06 Debiopharm S.A. Pharmaceutical composition in the form of microparticles
DE4004430A1 (de) 1990-02-09 1991-08-14 Schering Ag Aus polyaldehyden aufgebaute kontrastmittel
MY107937A (en) 1990-02-13 1996-06-29 Takeda Chemical Industries Ltd Prolonged release microcapsules.
JPH0426630A (ja) * 1990-05-19 1992-01-29 Wakiyou Kagaku Kogyo Kk 水性製剤におけるリゾチーム塩の安定化方法
US5410016A (en) 1990-10-15 1995-04-25 Board Of Regents, The University Of Texas System Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers
US5529914A (en) 1990-10-15 1996-06-25 The Board Of Regents The Univeristy Of Texas System Gels for encapsulation of biological materials
SE9200547L (sv) * 1992-02-25 1993-06-14 Perstorp Ab En farmaceutisk komposition med foerbaettrad biotillgaenglighet avseende inositolfosfat
JPH07507768A (ja) 1992-03-12 1995-08-31 アルカーメス　コントロールド　セラピューティクス，インコーポレイテッド Ａｃｔｈ含有マイクロスフェアの制御放出
ES2151541T3 (es) 1992-12-02 2001-01-01 Alkermes Inc Microesferas que contienen hormona del crecimiento de liberacion prolongada.
US5595760A (en) * 1994-09-02 1997-01-21 Delab Sustained release of peptides from pharmaceutical compositions
WO1996021440A1 (en) * 1995-01-09 1996-07-18 Alpha-Therapeutics, Inc. Methods for increasing the bioavailability of biological active agents
US5698213A (en) 1995-03-06 1997-12-16 Ethicon, Inc. Hydrogels of absorbable polyoxaesters
US6410044B1 (en) 1998-03-19 2002-06-25 Surmodics, Inc. Crosslinkable macromers
KR19990085365A (ko) * 1998-05-16 1999-12-06 허영섭 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법
US6461631B1 (en) 1999-11-16 2002-10-08 Atrix Laboratories, Inc. Biodegradable polymer composition
WO2002010177A1 (en) * 2000-08-01 2002-02-07 Gmp Companies, Inc. Ammonium salts of inositol hexaphosphate and uses thereof
IL140017A (en) * 2000-11-30 2009-09-22 Abraham J Domb Polyhedra
US6592899B2 (en) * 2001-10-03 2003-07-15 Macromed Incorporated PLA/PLGA oligomers combined with block copolymers for enhancing solubility of a drug in water
US7226624B2 (en) * 2002-07-24 2007-06-05 Rabinowitz Israel N Synergistic compositions from yeast-modified aqueous extracts from almond hulls
CA2733212C (en) * 2002-08-22 2014-01-07 Nutrition 21, Inc. Arginine silicate inositol complex and use thereof
AU2003286472A1 (en) 2002-10-17 2004-05-04 Alkermes Controlled Therapeutics, Inc. Ii Microencapsulation and sustained release of biologically active polypeptides
US20040097419A1 (en) * 2002-11-19 2004-05-20 Holger Petersen Organic compounds
BRPI0514297A (pt) * 2004-08-12 2008-06-10 Quest Pharmaceutical Services composições farmacêuticas para liberação controlada de compostos biologicamente ativos

Also Published As

Publication number Publication date
EP1786400A2 (de) 2007-05-23
RU2390355C2 (ru) 2010-05-27
AU2005271242A1 (en) 2006-02-16
JP2008511544A (ja) 2008-04-17
PT1786400E (pt) 2009-06-19
KR20070043881A (ko) 2007-04-25
RU2007105872A (ru) 2008-09-20
CN101035512A (zh) 2007-09-12
NZ553149A (en) 2010-01-29
AU2005271242B9 (en) 2012-04-12
KR101231856B1 (ko) 2013-02-08
US7964219B2 (en) 2011-06-21
DK1786400T3 (da) 2009-06-29
ES2323141T3 (es) 2009-07-07
SI1786400T1 (sl) 2009-08-31
EP1786400A4 (de) 2008-07-09
CN101035512B (zh) 2012-01-18
MX2007001760A (es) 2007-07-24
PL1786400T3 (pl) 2009-08-31
JP5053846B2 (ja) 2012-10-24
AU2005271242B2 (en) 2011-09-15
WO2006017852A3 (en) 2006-08-31
EP1786400B1 (de) 2009-03-11
ATE424848T1 (de) 2009-03-15
CA2576689A1 (en) 2006-02-16
HK1108638A1 (en) 2008-05-16
AU2005271242A2 (en) 2006-02-16
BRPI0514297A (pt) 2008-06-10
US20060034923A1 (en) 2006-02-16
CY1109425T1 (el) 2014-08-13
CA2576689C (en) 2012-10-09
WO2006017852A2 (en) 2006-02-16

Similar Documents

Publication Publication Date Title
DE602005013244D1 (de) Pharmazeutische zusammensetzungen für die kontroll
RS20070511A (en) Modified release pharmaceutical compositions and processes thereof
WO2007084460A8 (en) Pharmaceutical compositions with enhanced stability
UA110013C2 (uk) Застосування композиції для лікування шарко-марі-тута і пов'язаних з нею розладів
WO2004108162A3 (en) Controlled release pharmaceutical composition
WO2007048219A3 (en) Sustained drug release composition
RU2014133501A (ru) Способ лечения повышенного внутриглазного давления с помощью внутриглазной системы доставки лекарственного средства с замедленным высвобождением
BR112013016772B8 (pt) compostos, uso do composto e composição farmacêutica
WO2005034859A3 (en) Extended release formulations of opioids and method of use thereof
GEP20125628B (en) Pharmaceutical compositions containing antagonist anti-cd40 antibody
MX2010010026A (es) Agente para tratar enfermedad.
WO2009063222A3 (en) Solid compositions
GEP20115200B (en) Stable pharmaceutical composition containing docetaxel and a method of manufacturing the same
WO2005009357A3 (en) Controlled release compositions
ATE396967T1 (de) (5-(2-hydroxy-4-chlorbenzoyl)valeriansäure und deren salze, und zusammensetzungen zur zuführung von wirkstoffen, die diese verbindungen enthalten
WO2013036309A3 (en) Sustained release formulations for delivery of proteins to the eye and methods of preparing same
WO2007085629A3 (en) Use of hyaluronic acid as a carrier molecule for?different classes of therapeutic active agents
EP3219310A3 (de) Implantierbare arzneimittelabgabezusammensetzungen und behandlungsverfahren damit
UA96622C2 (ru) Твердые лекарственные формы, которые содержат алискирен, изготовленные способом сухого гранулирования
WO2006010084A3 (en) A system for delivering therapeutic agents into living cells and cell nuclei
RS70704A (en) Sustained/controlled release solid formulation as a novel drug delivery system with reduced risk of dose dumping
GB2446341A (en) Method and system for transdermal drug delivery
MX341642B (es) Composicion de liberacion sostenida que contiene peptidos como ingredientes activos.
TW200740440A (en) Novel combinations of medicaments for the treatment of respiratory diseases containing long-acting beta-agonists and at least one additional active ingredient
WO2008033058A3 (fr) Procédé permettant de produire une préparation d'insuline pour administration orale

Legal Events

Date Code Title Description
8364 No opposition during term of opposition